Trial · NCT07900620
T1 Colorectal Cancer After Local Excision: Decision Between Surgery and Active Surveillance (T1LDA Trial)
NCT07900620, Not applicable, Not yet recruiting, Tampere University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. T1 Colorectal Cancer After Local Excision: Decision Between Surgery and Active Surveillance (T1LDA Trial). Trials, record NCT07900620. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900620
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- T1 Colorectal Cancer After Local Excision: Decision Between Surgery and Active Surveillance (T1LDA Trial)
- NCT number
- NCT07900620
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 500 participants, estimated
- Lead sponsor
- Tampere University Hospital
- Conditions
- Colorectal Cancer
- Interventions
- Additional surgery
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Distant or extraluminal recurrence rate | 3 years | The primary endpoint is 3-year distant or extraluminal recurrence, defined as the occurrence of any distant recurrence or extraluminal local recurrence within 3 years of study enrollment. |
| Secondary | Recurrence-free survival (RFS) | 3 and 5 years | Time from study enrollment to the first occurrence of confirmed recurrence or colorectal cancer-related death. |
| Secondary | Disease-specific survival (DSS) | 3 and 5 years | Time from study enrollment to confirmed colorectal cancer-specific death. Deaths due to other causes will be treated as censoring events. |
| Secondary | Overall survival (OS) | 3 and 5 years | Time from study enrollment to death from any cause. |
| Secondary | Local, distant and overall recurrence | 3 and 5 years | The proportion of participants with confirmed local (intraluminal or extraluminal) recurrence, distant recurrence or overall recurrence during follow-up. Overall recurrence includes both local and distant recurrences. |
| Secondary | Rate of lymph node metastases | 3 and 5 years | The proportion of participants with histologically confirmed lymph node metastases identified in surgical specimens. |
| Secondary | Predictive value of predefined histopathological high-risk factors for histologically confirmed lymph node metastases. | 5 years | The predictive value of predefined histopathological high-risk features, including lymphovascular invasion, tumor budding, poor differentiation, and deep submucosal invasion, for histologically confirmed lymph node metastases will be evaluated. |
| Secondary | Complication and mortality rates (surgical- and non-surgical) | 30 and 90 days | The proportion of participants experiencing complications or death within 30 and 90 days after treatment allocation. Complications will be graded according to the Clavien-Dindo classification |
| Secondary | Long-term complication rates (surgical- and non-surgical) | 5 years | The proportion of participants experiencing treatment-related complications occurring more than 90 days after treatment allocation. |
| Secondary | Number and characteristics of salvage surgeries | 5 years | Number of salvage surgical procedures performed during follow-up, including indications and type of surgery. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900620
GET https://conductscience.org/api/trials/v1/NCT07900620/registered